HENRY FORD HEALTH SYSTEM
Center for Health Policy & Health Services Research

David Lanfear, MD, MS
Investigator

Contact Information:
Email:dlanfea1@hfhs.org
Phone: (313) 874-5454
Fax: (313) 874-7137

Recent Publications:

Jin YD, Hu EL, Peterson EL, Eng C, Levin AM, Wells K, Beckman K, Kumar R, Seibold MA, Karungi G, Zoratti A, Gaggin J, Campbell J, Galanter J, Chapela R, Rodriguez-Santana JR, Watson HG, Meade K, Lenoir M, Rodriguez-Cintron W, Avilla PC, Lanfear DE, Burchard EG, Williams LK.  Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients.  J Allergy Clin Immunol 2010;126(3):618-625 e

Alquasi F, Peterson E, Williams LK, Lanfear DE.  Comparing methods for identifying patients with heart failure using electronic data sources.  BMC Health Services Research.  2009;Dec. 18;9(1):237.

Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK.  Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.  Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47

Lanfear DE, Hasan R, Gupta RC, Williams C, Czerska B, Tita C, Bazari R, Sabbah HN.  Short term effects of milrinone on biomarkets of necrosis, apoptosis, and inflammation in patients with severe heart failure.  J Transl Med 2009;7:67

Steinke L, Lanfear DE, Dhanapal V, Kalus JS.  Effect of “energy drink” consumption on hemodynamic and electrocardiographic parameters in healthy young adults.  Ann Pharmacother, 2009;43:596-602

Biography:

DAVID E. LANFEAR, MD, MS, is member of the Advanced Heart Failure and Cardiac Transplantation section at the Henry Ford Heart and Vascular Institute in Detroit, MI.  Dr. Lanfear earned his medical degree from the University of Michigan Medical School, with election to Alpha Omega Alpha Honor Medical Society.  He then completed his internal medicine residency at Barnes-Jewish Hospital in St. Louis, and subsequently entered cardiovascular disease fellowship at Washington University in St. Louis.  There he completed a prolonged fellowship with advanced training in Cardiac Transplantation as well as 2 years of dedicated research training of Dr. Howard L. McLeod, focusing on applied pharmacogenetics and genomics.  Dr. Lanfear successfully spearheaded several projects during this period, publishing several first-author manuscripts in high impact journals including the Journal of the American Medical Association (JAMA) and the Journal of the American College of Cardiology.  Highlighting the importance of this work is the fact that the American Heart Association chose his JAMA work, titled “β2-Adrenergic Receptor Genotype and Survival among Patients Receiving β-Blocker Therapy after an Acute Coronary Syndrome” ,  as one of the top ten achievements of the year.  He also received several awards recognizing his early career success including the Burton Sobel award for excellence in cardiovascular research at Washington University, and being a finalist for Jay Cohn Young Investigator award through the Heart Failure Society of America.

Dr. Lanfear has continued is research dedication and productivity, now with 19 publications, 18 published abstracts, and 3 manuscripts currently under consideration. This productivity has been rewarded by successfully obtaining funding from several sources including a Heart Failure Society of America Research Fellowship grant, an American Heart Association Scientist Development grant, multiple industrial grants, and finally in 2008 a Career Development Award from the National Institutes of Health.  This grant continues Dr. Lanfear’s Focus on pharmacogenetics and is titled “Pharmacogenetics of the B-type Natriuretic Peptide Pathway”.  Since joining Henry Ford Heart and Vascular Institute in 2005 Dr. Lanfear has underscored his dedication to research by completing a Masters degree in Clinical Research Design and Statistical Analysis from the University of Michigan, School of Public Health in 2007.  This has enhanced his research skills and broadened his expertise.  He has appointments in the Health Services Research division and as Assistant Professor at Wayne State University, reflecting his academic achievement and broad expertise.  His development has been recognized externally as well and he has become highly involved in national academic societies.  He is a Fellow of the American College of Cardiology (FACC), an active member of the ACC Heart Failure and Transplant committee, the Michigan ACC Chapter Council, as well as a member of the Heart Failure Society of America Research Committee.  He is on the editorial board of the Journal of Cardiac Failure and has edited an issue of Heart Failure Reviews focused on cardiovascular pharmacogenetics.